Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-431 first-line selpercatinib versus platinum-pemetrexed with or without pembrolizumab in RET fusion-positive NSCLC
NL-OMON52946Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival by blinded independent central review. Started Feb 2021; status: recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52946.